KINDREDBIO IS FOCUSED ON NEXT GENERATION VETERINARY THERAPEUTIC BIOLOGICS, SUCH AS MONOCLONAL ANTIBODIES AND RECOMBINANT PROTEINS, FOR OUR CATS, DOGS, AND HORSES.
Next Generation Biologics
In humans, therapeutic biologics have revolutionized the practice of medicine, providing more effective and safer treatments for many diseases including various cancers as well as inflammatory and autoimmune disorders. KindredBio is focused on development of next generation veterinary therapeutic biologics, such as monoclonal antibodies and recombinant proteins, for our cats, dogs, and horses.
Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory. The DNA codes for protein which are inserted into the genome result in production of large quantities of recombinant protein through replication in living host cells in the laboratory. The recombinant protein produced is then purified and the final preparation administered to the animal (cat, dog, or horse) for targeted therapy. Unlike non-recombinant proteins purified directly from serum of the animals, recombinant proteins are produced in a controlled and sterile environment resulting in a uniform product with control of viral and bacterial contamination. The final preparation (drug formulation) is sterile and contains a highly pure and targeted drug.